1356 DM926, a novel anti-LILRB1/LILRB2 dual antagonist antibody, promotes adaptive and innate immune response to enhance anti-tumor activity in preclinical models

• Yi Xu,
• Dong Zhang,
• Nan Bing,
• Hong Chang,
• Sheng Yin,
• Guangan Hu,
• Quanju Zhao,
• Xiaochun Chen,
• Xiaodong Jiang

Affiliations

Yi Xu

2D2M Biotherapeutics Co., Suzhou, Jiangsu, China

Dong Zhang

1D2M Biotherapeutics, Natick, MA, USA

Nan Bing

1D2M Biotherapeutics, Natick, MA, USA

Hong Chang

2D2M Biotherapeutics Co., Suzhou, Jiangsu, China

Sheng Yin

1D2M Biotherapeutics, Natick, MA, USA

Guangan Hu

1D2M Biotherapeutics, Natick, MA, USA

Quanju Zhao

1D2M Biotherapeutics, Natick, MA, USA

Xiaochun Chen

1D2M Biotherapeutics, Natick, MA, USA

Xiaodong Jiang

1D2M Biotherapeutics, Natick, MA, USA